O	0	7	Primary
O	8	16	analysis
O	17	19	of
O	20	21	a
O	22	33	prospective
O	33	34	,
O	35	45	randomized
O	45	46	,
O	47	53	single
O	53	54	-
O	54	61	blinded
O	62	67	phase
O	68	70	II
O	71	76	trial
O	77	87	evaluating
O	88	91	the
B-intervention	92	96	HER2
I-intervention	97	104	peptide
I-intervention	105	108	GP2
I-intervention	109	116	vaccine
O	117	119	in
O	120	126	breast
O	127	133	cancer
O	134	142	patients
O	143	145	to
O	146	153	prevent
O	154	164	recurrence
O	164	165	.

O	166	169	GP2
O	170	172	is
O	173	174	a
O	175	179	HER2
O	179	180	-
O	180	187	derived
O	187	188	,
O	189	192	HLA
O	192	193	-
O	193	195	A2
O	195	196	+
O	197	207	restricted
O	208	215	peptide
O	215	216	.

O	217	222	Phase
O	223	224	I
O	225	232	studies
O	233	239	showed
O	240	243	GP2
O	244	256	administered
O	257	261	with
O	262	264	GM
O	264	265	-
O	265	268	CSF
O	269	271	to
O	272	274	be
O	275	279	safe
O	280	283	and
O	284	295	immunogenic
O	295	296	.

O	297	301	Here
O	302	304	we
O	305	311	report
O	312	315	the
O	316	323	primary
O	324	332	analysis
O	333	335	of
O	336	337	a
O	338	349	prospective
O	349	350	,
O	351	361	randomized
O	361	362	,
O	363	374	multicenter
O	375	380	phase
O	381	383	II
O	384	392	adjuvant
O	393	398	trial
O	399	408	conducted
O	409	411	to
O	412	421	determine
O	422	425	the
O	426	433	vaccine
O	433	434	'
O	434	435	s
O	436	444	efficacy
O	444	445	.

O	446	449	The
O	450	455	trial
O	456	464	enrolled
B-eligibility	465	468	HLA
I-eligibility	468	469	-
I-eligibility	469	471	A2
I-eligibility	471	472	+
I-eligibility	472	473	,
I-eligibility	474	484	clinically
I-eligibility	485	492	disease
I-eligibility	492	493	-
I-eligibility	493	497	free
I-eligibility	497	498	,
I-eligibility	499	503	node
I-eligibility	503	504	-
I-eligibility	504	512	positive
I-eligibility	513	516	and
I-eligibility	517	521	high
I-eligibility	521	522	-
I-eligibility	522	526	risk
I-eligibility	527	531	node
I-eligibility	531	532	-
I-eligibility	532	540	negative
I-eligibility	541	547	breast
I-eligibility	548	554	cancer
I-eligibility	555	563	patients
I-eligibility	564	568	with
I-eligibility	569	575	tumors
I-eligibility	576	586	expressing
I-eligibility	587	591	HER2
I-eligibility	592	593	(
I-eligibility	593	613	immunohistochemistry
I-eligibility	613	614	[
I-eligibility	614	617	IHC
I-eligibility	617	618	]
I-eligibility	619	620	1
I-eligibility	620	621	+
I-eligibility	621	622	-
I-eligibility	622	623	3
I-eligibility	623	624	+
I-eligibility	624	625	)
O	625	626	.

O	627	635	Patients
O	636	640	were
O	641	651	randomized
O	652	654	to
B-intervention	655	658	GP2
I-intervention	658	659	+
I-intervention	659	661	GM
I-intervention	661	662	-
I-intervention	662	665	CSF
O	666	672	versus
B-control	673	675	GM
I-control	675	676	-
I-control	676	679	CSF
I-control	680	685	alone
O	685	686	.

O	687	694	Disease
O	694	695	-
O	695	699	free
O	700	708	survival
O	709	710	(
O	710	713	DFS
O	713	714	)
O	715	718	was
O	719	727	analyzed
O	728	730	in
O	731	740	intention
O	740	741	-
O	741	743	to
O	743	744	-
O	744	749	treat
O	750	751	(
O	751	754	ITT
O	754	755	)
O	756	759	and
O	760	763	per
O	763	764	-
O	764	773	treatment
O	774	781	cohorts
O	781	782	;
O	783	786	pre
O	786	787	-
O	787	796	specified
O	797	805	subgroup
O	806	814	analyses
O	815	819	were
O	820	829	performed
O	830	833	for
O	834	842	patients
O	843	847	with
O	848	851	IHC
O	852	853	3
O	853	854	+
O	855	857	or
O	858	862	FISH
O	862	863	+
O	864	871	disease
O	871	872	.

O	873	876	The
O	877	882	trial
O	883	891	enrolled
B-total-participants	892	895	180
O	896	904	patients
O	904	905	;
B-intervention-participants	906	908	89
O	909	917	received
O	918	921	GP2
O	921	922	+
O	922	924	GM
O	924	925	-
O	925	928	CSF
O	929	932	and
B-control-participants	933	935	91
O	936	944	received
O	945	947	GM
O	947	948	-
O	948	951	CSF
O	952	957	alone
O	957	958	.

O	959	962	The
O	963	969	groups
O	970	974	were
O	975	979	well
O	979	980	-
O	980	987	matched
O	988	991	for
O	992	1009	clinicopathologic
O	1010	1025	characteristics
O	1025	1026	.

O	1027	1037	Toxicities
O	1038	1042	have
O	1043	1047	been
O	1048	1055	minimal
O	1055	1056	.

O	1057	1060	The
O	1061	1067	Kaplan
O	1067	1068	-
O	1068	1073	Meier
O	1074	1083	estimated
B-outcome	1084	1085	5
I-outcome	1085	1086	-
I-outcome	1086	1090	year
I-outcome	1091	1094	DFS
I-outcome	1095	1099	rate
O	1100	1102	in
O	1103	1106	the
O	1107	1110	ITT
O	1111	1119	analyses
O	1120	1123	was
B-iv-bin-percent	1124	1126	88
I-iv-bin-percent	1126	1127	%
O	1128	1129	(
O	1129	1131	95
O	1131	1132	%
O	1133	1135	CI
O	1135	1136	:
O	1136	1138	78
O	1138	1139	-
O	1139	1141	94
O	1141	1142	%
O	1142	1143	)
O	1144	1146	in
O	1147	1157	vaccinated
O	1158	1160	vs
O	1160	1161	.
B-cv-bin-percent	1162	1164	81
I-cv-bin-percent	1164	1165	%
O	1166	1167	(
O	1167	1169	95
O	1169	1170	%
O	1171	1173	CI
O	1173	1174	:
O	1174	1176	69
O	1176	1177	-
O	1177	1179	89
O	1179	1180	%
O	1180	1181	)
O	1182	1183	(
O	1183	1184	P
O	1185	1186	=
O	1187	1188	0
O	1188	1189	.
O	1189	1191	43
O	1191	1192	)
O	1193	1195	in
O	1196	1203	control
O	1204	1212	patients
O	1213	1218	after
O	1219	1220	a
O	1221	1223	34
O	1224	1229	month
O	1230	1236	median
O	1237	1243	follow
O	1243	1244	-
O	1244	1246	up
O	1246	1247	.

B-outcome	1248	1250	In
I-outcome	1251	1254	the
I-outcome	1255	1258	per
I-outcome	1258	1259	-
I-outcome	1259	1268	treatment
I-outcome	1269	1277	analysis
O	1277	1278	,
O	1279	1282	the
B-outcome	1283	1292	estimated
I-outcome	1293	1294	5
I-outcome	1294	1295	-
I-outcome	1295	1299	year
I-outcome	1300	1303	DFS
I-outcome	1304	1309	rates
O	1310	1314	were
B-iv-bin-percent	1315	1317	94
I-iv-bin-percent	1317	1318	%
O	1319	1320	(
O	1320	1322	95
O	1322	1323	%
O	1324	1326	CI
O	1326	1327	:
O	1327	1329	83
O	1329	1330	-
O	1330	1332	98
O	1332	1333	%
O	1333	1334	)
O	1335	1338	and
B-cv-bin-percent	1339	1341	85
I-cv-bin-percent	1341	1342	%
O	1343	1344	(
O	1344	1346	73
O	1346	1347	-
O	1347	1349	92
O	1349	1350	%
O	1350	1351	)
O	1352	1353	(
O	1353	1354	P
O	1355	1356	=
O	1357	1358	0
O	1358	1359	.
O	1359	1361	17
O	1361	1362	)
O	1362	1363	.

B-outcome	1364	1366	In
I-outcome	1367	1370	IHC
I-outcome	1371	1372	3
I-outcome	1372	1373	+
I-outcome	1373	1374	/
I-outcome	1374	1378	FISH
I-outcome	1378	1379	+
I-outcome	1380	1388	patients
I-outcome	1388	1389	,
I-outcome	1390	1393	the
I-outcome	1394	1403	estimated
I-outcome	1404	1405	5
I-outcome	1405	1406	-
I-outcome	1406	1410	year
I-outcome	1411	1414	DFS
I-outcome	1415	1419	rate
O	1420	1423	was
B-iv-bin-percent	1424	1426	94
I-iv-bin-percent	1426	1427	%
O	1428	1429	(
O	1429	1431	82
O	1431	1432	-
O	1432	1434	98
O	1434	1435	%
O	1435	1436	)
O	1437	1439	in
O	1440	1450	vaccinated
O	1451	1459	patients
O	1460	1461	(
O	1461	1462	n
O	1463	1464	=
B-intervention-participants	1465	1467	51
O	1467	1468	)
O	1469	1471	vs
O	1471	1472	.
B-cv-bin-percent	1473	1475	89
I-cv-bin-percent	1475	1476	%
O	1477	1478	(
O	1478	1480	71
O	1480	1481	-
O	1481	1483	96
O	1483	1484	%
O	1484	1485	)
O	1486	1488	in
O	1489	1496	control
O	1497	1505	patients
O	1506	1507	(
O	1507	1508	n
O	1509	1510	=
B-control-participants	1511	1513	50
O	1513	1514	)
O	1514	1515	,
O	1516	1517	(
O	1517	1518	P
O	1519	1520	=
O	1521	1522	0
O	1522	1523	.
O	1523	1525	86
O	1525	1526	)
O	1527	1529	in
O	1530	1533	the
B-outcome	1534	1537	ITT
I-outcome	1538	1546	analyses
O	1547	1550	and
B-iv-bin-percent	1551	1554	100
I-iv-bin-percent	1554	1555	%
O	1556	1558	vs
O	1558	1559	.
B-cv-bin-percent	1560	1562	89
I-cv-bin-percent	1562	1563	%
O	1564	1565	(
O	1565	1567	71
O	1567	1568	-
O	1568	1570	96
O	1570	1571	%
O	1571	1572	)
O	1573	1575	in
O	1576	1586	vaccinated
O	1587	1589	vs
O	1589	1590	.
O	1591	1598	control
O	1599	1607	patients
O	1608	1610	in
O	1611	1614	the
O	1615	1618	per
O	1618	1619	-
O	1619	1628	treatment
O	1629	1637	analyses
O	1638	1639	(
O	1639	1640	P
O	1641	1642	=
O	1643	1644	0
O	1644	1645	.
O	1645	1647	08
O	1647	1648	)
O	1648	1649	.

O	1650	1655	While
O	1656	1659	the
O	1660	1667	overall
O	1668	1671	ITT
O	1672	1680	analysis
O	1681	1684	did
O	1685	1688	not
O	1689	1700	demonstrate
O	1701	1708	benefit
O	1709	1711	to
O	1712	1723	vaccination
O	1723	1724	,
O	1725	1729	this
O	1730	1735	trial
O	1736	1745	confirmed
O	1746	1750	that
O	1751	1754	the
O	1755	1758	GP2
O	1759	1766	vaccine
O	1767	1769	is
O	1770	1774	safe
O	1775	1778	and
O	1779	1787	suggests
O	1788	1792	that
O	1793	1804	vaccination
O	1805	1808	may
O	1809	1813	have
O	1814	1822	clinical
O	1823	1831	activity
O	1831	1832	,
O	1833	1845	particularly
O	1846	1848	in
O	1849	1857	patients
O	1858	1862	with
O	1863	1867	HER2
O	1868	1882	overexpression
O	1883	1886	who
O	1887	1895	received
O	1896	1899	the
O	1900	1904	full
O	1905	1912	vaccine
O	1913	1919	series
O	1920	1921	(
O	1921	1923	ie
O	1924	1927	per
O	1927	1928	-
O	1928	1937	treatment
O	1938	1943	group
O	1943	1944	)
O	1944	1945	.
